FULCRUM THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
FULCRUM THERAPEUTICS, INC. (FULC) reported Net Income (Loss) Available to Common Stockholders, Basic of -$70.82 million for the 12-month period ending 2020-12-31, per its 10-K/A filed 2023-06-23.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-06-23
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$17.72M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$18.96M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$15.69M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$18.45M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$70.82M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$89.81M.
- FULCRUM THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$39.15M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$17.72M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | -$36.68M derived: sum of 2 quarters · filed 2023-06-23 | -$52.37M derived: sum of 3 quarters · filed 2023-06-23 | -$70.82M 10-K/A · filed 2023-06-23 |
| 2020-09-30 | -$18.96M 10-Q · filed 2020-11-10 | -$34.65M derived: sum of 2 quarters · filed 2020-11-10 | -$53.10M 10-Q · filed 2020-11-10 | -$69.22M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | -$15.69M 10-Q · filed 2020-08-11 | -$34.14M 10-Q · filed 2020-08-11 | -$50.26M derived: sum of 3 quarters · filed 2023-06-23 | -$67.60M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | -$18.45M 10-Q · filed 2020-05-13 | -$34.58M derived: sum of 2 quarters · filed 2023-06-23 | -$51.91M derived: sum of 3 quarters · filed 2023-06-23 | -$68.37M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | -$16.12M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | -$33.46M derived: sum of 2 quarters · filed 2023-06-23 | -$49.92M derived: sum of 3 quarters · filed 2023-06-23 | -$89.81M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | -$17.34M 10-Q · filed 2020-11-10 | -$33.80M derived: sum of 2 quarters · filed 2020-11-10 | -$73.68M 10-Q · filed 2020-11-10 | -$85.36M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$16.46M 10-Q · filed 2020-08-11 | -$56.34M 10-Q · filed 2020-08-11 | -$68.03M derived: sum of 3 quarters · filed 2020-08-11 | -$78.83M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$39.88M 10-Q · filed 2020-05-13 | -$51.57M derived: sum of 2 quarters · filed 2020-05-13 | -$62.37M derived: sum of 3 quarters · filed 2020-05-13 | -$71.26M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$11.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$22.48M derived: sum of 2 quarters · filed 2020-03-05 | -$31.38M derived: sum of 3 quarters · filed 2020-03-05 | -$39.15M 10-K · filed 2020-03-05 |
| 2018-09-30 | -$10.80M 10-Q · filed 2019-11-14 | -$19.70M derived: sum of 2 quarters · filed 2019-11-14 | -$27.46M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$8.90M 10-Q · filed 2019-08-26 | -$16.66M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |